



# Model List of Essential Medicines

## Abacavir

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abacavir + lamivudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abacavir + lamivudine + lopinavir + ritonavir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Aciclovir

Section	Indications
Antiherpes medicines Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt) Oral > Liquid: 200 mg per 5 mL Oral > Solid: 200 mg tablet	Zoster Varicella Herpes simplex infections

## Atazanavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Atazanavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Daclatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)	Chronic hepatitis C

## Daclatasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 60 mg + 400 mg	Chronic hepatitis C

## Darunavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Dasabuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 250 mg tablet	Chronic hepatitis C

## Didanosine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution  Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Dolutegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Dolutegravir + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors Oral > Solid: 600 mg tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz + emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz + lamivudine + tenofovir

Section	Indications
<p><b>Fixed-dose combinations of antiretrovirals</b> Oral &gt; Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)</p>	<p>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</p> <p>Therapeutic equivalent to <a href="#">efavirenz + emtricitabine + tenofovir</a> for</p> <p>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</p>

## Elbasvir + grazoprevir

Section	Indications
<p>Medicines for hepatitis C &gt; Non-pangenotypic direct-acting antiviral combinations Oral &gt; Solid: 50 mg + 100 mg</p>	Chronic hepatitis C

## Emtricitabine

Section	Indications
<p>Antiretrovirals &gt; Nucleoside/Nucleotide reverse transcriptase inhibitors Oral &gt; Liquid: 10 mg per mL Oral &gt; Solid: 200 mg</p>	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + rilpivirine + tenofovir alafenamide

Section	Indications
<p><b>Fixed-dose combinations of antiretrovirals</b> Oral &gt; Solid: 200 mg + 25 mg + 25 mg</p>	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section	Indications
<p><b>Fixed-dose combinations of antiretrovirals</b> Oral &gt; Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)</p>	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + tenofovir

Section	Indications
<p><b>Fixed-dose combinations of antiretrovirals</b> Oral &gt; Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)</p>	<p>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</p> <p>Contact with or exposure to human immunodeficiency virus</p>

## Emtricitabine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Entecavir

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 0.05 mg per mL Oral > Solid: 0.5 mg; 1 mg	Chronic hepatitis B

## Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 50 mg + 20 mg granules Oral > Solid > tablet: 100 mg + 40 mg	Chronic hepatitis C

## Indinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 400 mg (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section	Indications
Medicines for prevention of HIV-related opportunistic infections Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)	Other specified prophylactic measures

## Lamivudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 50 mg per 5 mL Oral > Solid: 150 mg tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Lamivudine + nevirapine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals	Therapeutic equivalent to emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
	Therapeutic equivalent to emtricitabine + tenofovir for Contact with or exposure to human immunodeficiency virus

## Lamivudine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Ledipasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 90 mg + 400 mg tablet	Chronic hepatitis C

## Lopinavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable) Oral > Solid > dosage form: 40 mg + 10 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Nelfinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 250 mg (as mesilate) Oral > Other: 50 mg per g oral powder	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Nevirapine

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors Oral > Liquid: 50 mg per 5 mL Oral > Solid > dispersible tablet: 50 mg Oral > Solid > tablet: 200 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Ombitasvir + paritaprevir + ritonavir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet	Chronic hepatitis C

## Oseltamivir

Section	Indications
Other antivirals Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)	Influenza due to identified seasonal influenza virus

## Pegylated interferon alfa (2a)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe	Chronic hepatitis C

## Pegylated interferon alfa (2b)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe	Chronic hepatitis C

## Raltegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Liquid: 100 mg granules for oral suspension Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Ravidasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations	Chronic hepatitis C
Oral > Solid > tablet: 200 mg	

## Ribavirin

Section	Indications
Other antivirals	
Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution	Viral haemorrhagic fever, not elsewhere classified
Oral > Solid: 200 mg; 400 mg; 600 mg	
Medicines for hepatitis C > Other antivirals for hepatitis C	Chronic hepatitis C
Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution	
Oral > Solid: 200 mg; 400 mg; 600 mg	

## Ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors	
Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Saquinavir

Section	Indications
Antiretrovirals > Protease inhibitors	
Oral > Solid: 200 mg; 500 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Simeprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations	Chronic hepatitis C
Oral > Solid: 150 mg	

## Sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg; 400 mg	Chronic hepatitis C

## Sofosbuvir + velpatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg	Chronic hepatitis C

## Stavudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 5 mg per 5 mL powder for oral solution Oral > Solid: 15 mg; 20 mg; 30 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Tenofovir alafenamide

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 25 mg	Chronic hepatitis B

## Tenofovir disoproxil fumarate

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Chronic hepatitis B

## Valaciclovir

Section	Indications
Antiherpes medicines	<p>Therapeutic equivalent to <a href="#">aciclovir</a> for</p> <p><a href="#">Zoster</a></p> <p>Therapeutic equivalent to <a href="#">aciclovir</a> for</p> <p><a href="#">Varicella</a></p> <p>Therapeutic equivalent to <a href="#">aciclovir</a> for</p> <p><a href="#">Herpes simplex infections</a></p>

## Valganciclovir

Section	Indications
<p>Other antivirals</p> <p>Oral &gt; Liquid: 50 mg per mL powder for oral solution</p> <p>Oral &gt; Solid &gt; tablet: 450 mg</p>	<p><a href="#">Cytomegaloviral retinitis</a></p>

## Zidovudine

Section	Indications
<p>Antiretrovirals &gt; Nucleoside/Nucleotide reverse transcriptase inhibitors</p> <p>Parenteral &gt; General injections &gt; IV: 10 mg per mL in 20 mL vial solution for IV infusion</p> <p>Oral &gt; Liquid: 50 mg per 5 mL</p> <p>Oral &gt; Solid &gt; tablet: 300 mg</p> <p>Oral &gt; Solid &gt; capsule: 250 mg</p>	<p><a href="#">Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</a></p>